Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

5(83.3%)

Phase 3

1(16.7%)

6Total

Phase 1(5)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04307576Phase 3Recruiting

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Role: collaborator

NCT06923111Recruiting

PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

Role: lead

NCT03763656Phase 1Completed

Pharmacokinetics of Oral Hydroxyurea Solution

Role: lead

NCT03291080Phase 1Completed

Oral Liquid 13-cis-retinoic Acid (13-CRA)

Role: lead

NCT03930264Phase 1Completed

Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)

Role: lead

NCT02500680Phase 1Unknown

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

Role: collaborator

NCT01697020Phase 1Completed

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Role: lead

All 7 trials loaded